CONCLUSIONS: Our results indicate that buprenorphine/naloxone treatment is a promising possibility for patients in need of opiate-substitution treatment.
PMID: 22427466 [PubMed – indexed for MEDLINE] (Source: Neuropsychopharmacologia Hungarica)

Updated Date: Dec 10, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Updated Date: Dec 10, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

ConclusionsAmong patients with opioid use disorder in Iran, sublingual buprenorphine/naloxone was associated with greater number of opioid‐negative urine tests and treatment retention than oral naltrexone, but not significantly greater initial abstinence duration or proportions with sustained abstinence. This article is protected by copyright. All rights reserved. (Source: Addiction)

ConclusionsAmong patients with opioid use disorder in Iran, sublingual buprenorphine/naloxone was associated with greater number of opioid‐negative urine tests and treatment retention than oral naltrexone, but not significantly greater initial abstinence duration or proportions with sustained abstinence. This article is protected by copyright. All rights reserved. (Source: Addiction)

ConclusionsA randomized controlled trial in a syringe exchange programme showed no evidence that a strength‐based case management intervention improved attendance for treatment over referral alone. Attendance rates were high in both groups. This article is protected by copyright. All rights reserved. (Source: Addiction)

ConclusionsA randomized controlled trial in a syringe exchange programme showed no evidence that a strength‐based case management intervention improved attendance for treatment over referral alone. Attendance rates were high in both groups. This article is protected by copyright. All rights reserved. (Source: Addiction)

ConclusionsThere are few differences in long‐term outcomes between buprenorphine and methadone treatment for opioid dependence, and treatment with each medication is associated with a strong reduction in opioid use. This article is protected by copyright. All rights reserved. (Source: Addiction)

ConclusionsThere are few differences in long‐term outcomes between buprenorphine and methadone treatment for opioid dependence, and treatment with each medication is associated with a strong reduction in opioid use. This article is protected by copyright. All rights reserved. (Source: Addiction)

ConclusionsThere are few differences in long‐term outcomes between buprenorphine and methadone treatment for opioid dependence, and treatment with each medication is associated with a strong reduction in opioid use. This article is protected by copyright. All rights reserved. (Source: Addiction)